Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 31Recruiting 25Active not recruiting 20Terminated 8Not yet recruiting 5Unknown 4Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 3Surgical Procedures, Operative 2Radiotherapy 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Doxorubicin 2Cyclophosphamide 2titanium silicide 1sargramostim 1exemestane 1eribulin 1cemiplimab 1Vincristine 1Taxes 1Tamoxifen 1Surveys and Questionnaires 1Specimen Handling 1S 1 (combination) 1Rituximab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Prednisone 1Prednisolone 1Passive Cutaneous Anaphylaxis 1Neoadjuvant Therapy 1Morphine 1Methylprednisolone 1Methotrexate 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Suspended × 130-nm albumin-bound paclitaxel × Clear all
NCT03777579 2019-08-08

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Suspended
375 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡